Mobile

NeoALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) study A randomized, multicentre open-label phase III study of neoadjuvant lapatinib, trastuzumab and their combination plus p...

Mise à jour : Il y a 4 ans
Référence : EUCTR2006-000564-81

NeoALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) study A randomized, multicentre open-label phase III study of neoadjuvant lapatinib, trastuzumab and their combination plus paclitaxel in women with HER2/ErbB2 positive primary breast cancer

Femme Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To evaluate and compare the rate of pathological complete response (pCR) at the time of surgery in patients with ErbB2 overexpressing or amplified operable breast cancer randomised between the study treatment arms.

Critère d'inclusion

  • Women with primary ErbB2 overexpressing and/or gene amplified breast cancer > 2 cm diameter who have not undergone previous treatment for invasive breast cancer

Liens